Nisa Investment Advisors LLC raised its position in shares of Qiagen NV (NASDAQ:QGEN) by 4.7% during the second quarter, according to its most recent filing with the SEC. The fund owned 13,400 shares of the company’s stock after buying an additional 600 shares during the period. Nisa Investment Advisors LLC’s holdings in Qiagen NV were worth $292,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Private Bank & Trust Co. boosted its position in shares of Qiagen NV by 17.8% in the second quarter. Private Bank & Trust Co. now owns 10,609 shares of the company’s stock worth $231,000 after buying an additional 1,606 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Qiagen NV by 25.2% in the first quarter. Royal Bank of Canada now owns 7,712 shares of the company’s stock worth $173,000 after buying an additional 1,553 shares during the last quarter. Bellevue Group AG acquired a new position in shares of Qiagen NV during the first quarter worth about $2,044,000. HBK Investments L P acquired a new position in shares of Qiagen NV during the first quarter worth about $344,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Qiagen NV by 59.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,448,832 shares of the company’s stock worth $32,366,000 after buying an additional 539,870 shares during the last quarter. 58.76% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Qiagen NV (NASDAQ:QGEN) traded down 0.78% during midday trading on Friday, reaching $26.66. 453,837 shares of the company’s stock traded hands. The firm has a market cap of $6.24 billion, a PE ratio of 53.32 and a beta of 0.90. The company has a 50 day moving average of $26.76 and a 200 day moving average of $23.43. Qiagen NV has a 52-week low of $19.94 and a 52-week high of $28.04.
Qiagen NV (NASDAQ:QGEN) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.01. Qiagen NV had a net margin of 9.13% and a return on equity of 9.21%. The firm earned $334.40 million during the quarter, compared to analysts’ expectations of $326.73 million. During the same period in the prior year, the company posted $0.26 EPS. The company’s revenue was up 4.7% on a year-over-year basis. On average, equities analysts predict that Qiagen NV will post $1.09 EPS for the current fiscal year.
A number of brokerages have recently weighed in on QGEN. DZ Bank AG reissued a “buy” rating on shares of Qiagen NV in a research report on Monday, September 19th. Commerzbank AG reissued a “buy” rating on shares of Qiagen NV in a research report on Friday, September 16th. Zacks Investment Research raised shares of Qiagen NV from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research report on Wednesday, September 14th. Morgan Stanley set a $30.00 price target on shares of Qiagen NV and gave the stock a “buy” rating in a research report on Sunday, September 11th. Finally, Jefferies Group reissued a “hold” rating on shares of Qiagen NV in a research report on Thursday, August 4th. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $25.36.
Qiagen NV Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).
Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.